{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:01:59Z","timestamp":1783958519883,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.coph.2026.102605","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:23:13Z","timestamp":1767889393000},"page":"102605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["CPX-351: From preclinical studies to future directions"],"prefix":"10.1016","volume":"87","author":[{"given":"A.","family":"Sperotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ciotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gottardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2026.102605_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/ajh.24246","article-title":"Acute myeloid leukemia-major progress over four decades and glimpse into the future","volume":"91","author":"Kantarjian","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.coph.2026.102605_bib2","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1007\/s00277-021-04565-1","article-title":"Allogeneic hematopoietic stem cell transplantation improves long-term outcomes for relapsed AML patients across all ages: results from two East Germany Study Group Hematology and Oncology (OSHO) trials","volume":"100","author":"Heinicke","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.coph.2026.102605_bib3","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1200\/JCO.2012.42.2907","article-title":"Acute myeloid leukemia (AML): different treatment strategy versus a common standard arm-combined prospective analysis by the German AML inter-group","volume":"30","author":"Buchner","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2026.102605_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for the novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.coph.2026.102605_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.24.00235","article-title":"Single or double induction with 3+7 containing standard or high-dose daunorubicin for newly diagnosed AML: the randomized DaunoDouble trial by the study alliance leukemia","volume":"43","author":"Rollig","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2026.102605_bib6","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1182\/bloodadvances.2024014901","article-title":"Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML","volume":"9","author":"Marconi","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2026.102605_bib7","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.2024026700","article-title":"Venetoclax plus daunorubicin and cytarabine for newly diagnosed cute myeloid leukemia: results of a phase 1b study","volume":"145","author":"Mantzaris","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.coph.2026.102605_bib8","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood.2024027217","article-title":"Venetoclax and decitabine vs intensive chemotherapy ad induction for young patients with newly diagnosed AML","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.coph.2026.102605_bib9","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-06-0118","article-title":"Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice","volume":"5","author":"Mayer","year":"2006","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.coph.2026.102605_bib10","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2217\/fon-2017-0607","article-title":"Improving combinations cancer therapy: the CombiPlex development platfor","volume":"14","author":"Tolcher","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.coph.2026.102605_bib11","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2026.102605_bib12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3727\/000000006783980937","article-title":"Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios","volume":"16","author":"Harasym","year":"2007","journal-title":"Oncol Res"},{"key":"10.1016\/j.coph.2026.102605_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","article-title":"In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy","volume":"33","author":"Tardi","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.coph.2026.102605_bib14","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","article-title":"FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia","volume":"25","author":"Krauss","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2026.102605_bib15","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","article-title":"Leukemia \u2013 selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine: daunorubicin formulation, in bone marrow xenografts","volume":"34","author":"Lim","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.coph.2026.102605_bib16","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1158\/0008-5472.CAN-07-5528","article-title":"Two distinct molecular mechanisms underlying cytarabine resistance in humen leukemic cells","volume":"68","author":"Cai","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.coph.2026.102605_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2020.102275","article-title":"Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals","author":"Wang","year":"2020","journal-title":"Nonomedicine"},{"key":"10.1016\/j.coph.2026.102605_bib18","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.exphem.2011.04.001","article-title":"Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells","volume":"39","author":"Kim","year":"2011","journal-title":"Exp Hematol"},{"key":"10.1016\/j.coph.2026.102605_bib19","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","article-title":"First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia","volume":"28","author":"Feldman","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2026.102605_bib20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cncr.28974","article-title":"Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML","volume":"15","author":"Cortes","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.coph.2026.102605_bib21","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.coph.2026.102605_sref22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomized, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Hematol"},{"key":"10.1016\/j.coph.2026.102605_sref23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-022-01361-w","article-title":"Efficacy and safety of CPX-351 versus 7+3 chemotherapy by European LeukemiaNet2017 risk subgroups in older adults with newly diagnosed, high-risk\/secondary AML: post hoc analysis of a randomized, phase 3 trial","volume":"15","author":"Cortes","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.coph.2026.102605_sref24","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1182\/bloodadvances.2021006468","article-title":"Transplant outcomes after CPX-351 vs 7+3 in older adults with newly diagnosed high-risk and\/or secondary AML","volume":"6","author":"Uy","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2026.102605_bib25","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/bloodadvances.2023010276","article-title":"A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial","volume":"7","author":"Othman","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2026.102605_bib26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-020-00361-8","article-title":"CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation. Results of the Italian compassionate use program","volume":"10","author":"Guolo","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.coph.2026.102605_bib27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","article-title":"Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric Franch cohort","volume":"5","author":"Chiche","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2026.102605_sref28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41408-021-00558-5","article-title":"Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia","volume":"11","author":"Rautenberg","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.coph.2026.102605_bib29","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/bjh.19622","article-title":"CREST-UK: real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK","volume":"205","author":"Mehta","year":"2024","journal-title":"Br J Maematol"},{"key":"10.1016\/j.coph.2026.102605_bib30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41408-025-01274-0","article-title":"Real-world experience with forst-line CPX-351 treatment in patients with acute myeloid leukemia-long- term follow-up with focus on younger patients","volume":"15","author":"Rautenberg","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.coph.2026.102605_bib31","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/bloodadvances.2024014279","article-title":"Long-term real-world evidence of CPX-351 of high \u2013 risk patients with AML identified high rate of negative MRD and prolonged OS","author":"Cluzeau","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2026.102605_bib32","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/ajh.70083","article-title":"Real world study on the best CPX-351 treatment duration and timimg for allogeneic stem cell transplantation","volume":"100","author":"Guolo","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.coph.2026.102605_bib33","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/cancers16050915","article-title":"CPX-351 pharmacokinetics and safety in adults with hematological malignancies and renal function impairment: phase 1 trial","volume":"16","author":"Solomon","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.coph.2026.102605_bib34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00280-019-03856-9","article-title":"A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias","volume":"84","author":"Lin","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.coph.2026.102605_bib35","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000968972.17880.6c","article-title":"Cardiotoxicity of CPX-351 vs 7+3 in patients with untreated high-risk acute myeloid leukemia","volume":"7","author":"Mitchell","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.coph.2026.102605_bib36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/cid\/ciz777","article-title":"Gut microbiome signatures are predictive of infectious risk following induction therapy for acute myeloid leukemia","volume":"71","author":"Galloway-Pena","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2026.102605_bib37","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1182\/bloodadvances.2021006783","article-title":"Lasting shift in the gut microbiota in patients with acute myeloid leukemia","volume":"6","author":"Rashidi","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2026.102605_bib38","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1038\/s41598-019-42652-6","article-title":"Dysbiosis patterns during re-induction\/salvage versus induction chemotherapy for acute leukemia","volume":"9","author":"Rashidi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2026.102605_sref39","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood.2023021380","article-title":"CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis","volume":"143","author":"Renga","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coph.2026.102605_bib40","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomized, open-label, phase 3 study","volume":"21","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2026.102605_bib41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2024-207962","article-title":"Combination of CPX-351 and gemtuzumab ozogamicin in relapsed\/refractory acute myeloid leukemia and post hypomethylating agent failure high-risk myelodysplastic syndrome","volume":"144","author":"Senapati","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coph.2026.102605_bib42","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2024-206161","article-title":"Phase 1\/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed acute myeloid leukemia","volume":"144","author":"Chan","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coph.2026.102605_bib43","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","article-title":"Discovery of AG-120 (ivosidenib): a first -in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers","volume":"9","author":"Popovici-Muller","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.coph.2026.102605_bib44","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.coph.2026.102605_bib45","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2024-209157","article-title":"Phase 1b\/II study of CPX-351 plus venetoclax in patients with relapsed\/refractory acute myeloid leukemia","volume":"144","author":"Bharathi","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coph.2026.102605_bib46","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood-2018-99-117772","article-title":"TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia","volume":"132","author":"Goldberg","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.coph.2026.102605_bib47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2019-124500","article-title":"Genetic characteristics and outcomes by mutation staus in a phase 3 study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk\/secondary acute myeloid leukemia","volume":"124","author":"Lindsley","year":"2019","journal-title":"Blood"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489226000019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489226000019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:13:48Z","timestamp":1773407628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489226000019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":47,"alternative-id":["S1471489226000019"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2026.102605","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CPX-351: From preclinical studies to future directions","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2026.102605","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102605"}}